Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Umana

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Blood|September 28, 2011
CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101Margot Jak, Gregor G W van Bochove, Eric A Reits, et al.
Oncoimmunology|September 2, 2025
Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapiesIdil Hutter-Karakoc, Eleni Maria Varypataki, Aparna Neelakandhan, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2011
Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strainsJürgen Schanzer, Andreas Jekle, Junichi Nezu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2016
In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor KillingSteffi Lehmann, Ramanil Perera, Hans-Peter Grimm, et al.
The Journal of Biological Chemistry|May 21, 2014
A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular propertiesJuergen M Schanzer, Katharina Wartha, Rebecca Croasdale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2011
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumorsLuis G Paz-Ares, Carlos Gomez-Roca, Jean-Pierre Delord, et al.
Cancer Immunology Research|August 9, 2015
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory ReceptorsDaniela S Thommen, Jens Schreiner, Philipp Müller, et al.
Blood|March 30, 2011
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodiesGerhard Niederfellner, Alfred Lammens, Olaf Mundigl, et al.
Journal for Immunotherapy of Cancer|January 22, 2022
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacyGabrielle Leclercq, Hélène Haegel, Alberto Toso, et al.
Journal of Autoimmunity|November 18, 2018
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune diseaseLaurence B Peterson, Charles J M Bell, Sarah K Howlett, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Blood|September 28, 2011
CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101Margot Jak, Gregor G W van Bochove, Eric A Reits, et al.
Oncoimmunology|September 2, 2025
Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapiesIdil Hutter-Karakoc, Eleni Maria Varypataki, Aparna Neelakandhan, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2011
Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strainsJürgen Schanzer, Andreas Jekle, Junichi Nezu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2016
In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor KillingSteffi Lehmann, Ramanil Perera, Hans-Peter Grimm, et al.
The Journal of Biological Chemistry|May 21, 2014
A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular propertiesJuergen M Schanzer, Katharina Wartha, Rebecca Croasdale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2011
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumorsLuis G Paz-Ares, Carlos Gomez-Roca, Jean-Pierre Delord, et al.
Cancer Immunology Research|August 9, 2015
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory ReceptorsDaniela S Thommen, Jens Schreiner, Philipp Müller, et al.
Blood|March 30, 2011
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodiesGerhard Niederfellner, Alfred Lammens, Olaf Mundigl, et al.
Journal for Immunotherapy of Cancer|January 22, 2022
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacyGabrielle Leclercq, Hélène Haegel, Alberto Toso, et al.
Journal of Autoimmunity|November 18, 2018
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune diseaseLaurence B Peterson, Charles J M Bell, Sarah K Howlett, et al.
Pageof 5